JP2009536627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536627A5 JP2009536627A5 JP2009508191A JP2009508191A JP2009536627A5 JP 2009536627 A5 JP2009536627 A5 JP 2009536627A5 JP 2009508191 A JP2009508191 A JP 2009508191A JP 2009508191 A JP2009508191 A JP 2009508191A JP 2009536627 A5 JP2009536627 A5 JP 2009536627A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- bond
- alkylene
- alkynylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*1=CC=CC(c(nc(N(*)**)nc2)c2-c2ccccc2)=CC1 Chemical compound C*1=CC=CC(c(nc(N(*)**)nc2)c2-c2ccccc2)=CC1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006021874.4 | 2006-05-11 | ||
| DE102006021874A DE102006021874B4 (de) | 2006-05-11 | 2006-05-11 | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PCT/EP2007/003804 WO2007131620A1 (de) | 2006-05-11 | 2007-04-30 | 4,5-diphenyl-pyrimidinyl-amino substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536627A JP2009536627A (ja) | 2009-10-15 |
| JP2009536627A5 true JP2009536627A5 (enExample) | 2013-05-16 |
| JP5277159B2 JP5277159B2 (ja) | 2013-08-28 |
Family
ID=38326940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508191A Expired - Fee Related JP5277159B2 (ja) | 2006-05-11 | 2007-04-30 | ４，５−ジフェニル−ピリミジニルアミノ置換カルボン酸類、それらの製造方法及び医薬品としての使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7713988B2 (enExample) |
| EP (1) | EP2024340B1 (enExample) |
| JP (1) | JP5277159B2 (enExample) |
| KR (1) | KR20090006845A (enExample) |
| CN (1) | CN101421251B (enExample) |
| AR (1) | AR060992A1 (enExample) |
| AU (1) | AU2007250211B2 (enExample) |
| BR (1) | BRPI0711393A2 (enExample) |
| CA (1) | CA2651657A1 (enExample) |
| DE (1) | DE102006021874B4 (enExample) |
| IL (1) | IL195177A0 (enExample) |
| MX (1) | MX2008014101A (enExample) |
| MY (1) | MY148096A (enExample) |
| NO (1) | NO20085066L (enExample) |
| TW (1) | TW200815366A (enExample) |
| UY (1) | UY30339A1 (enExample) |
| WO (1) | WO2007131620A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
| AU2008241490B2 (en) | 2007-04-16 | 2011-07-21 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2702047C (en) | 2007-10-10 | 2012-04-17 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
| US8450522B2 (en) | 2008-03-06 | 2013-05-28 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| WO2010045258A2 (en) | 2008-10-15 | 2010-04-22 | Amgen Inc. | Spirocyclic gpr40 modulators |
| MX2011006006A (es) * | 2008-12-08 | 2011-09-08 | Euroscreen Sa | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
| EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2499497A1 (en) * | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| NZ550114A (en) * | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| DE102004039789A1 (de) * | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
2006
- 2006-05-11 DE DE102006021874A patent/DE102006021874B4/de not_active Expired - Fee Related
-
2007
- 2007-04-30 WO PCT/EP2007/003804 patent/WO2007131620A1/de not_active Ceased
- 2007-04-30 MX MX2008014101A patent/MX2008014101A/es not_active Application Discontinuation
- 2007-04-30 KR KR1020087027548A patent/KR20090006845A/ko not_active Abandoned
- 2007-04-30 BR BRPI0711393-5A patent/BRPI0711393A2/pt not_active IP Right Cessation
- 2007-04-30 CN CN2007800133035A patent/CN101421251B/zh not_active Expired - Fee Related
- 2007-04-30 CA CA002651657A patent/CA2651657A1/en not_active Abandoned
- 2007-04-30 EP EP07724731A patent/EP2024340B1/de not_active Not-in-force
- 2007-04-30 AU AU2007250211A patent/AU2007250211B2/en not_active Ceased
- 2007-04-30 JP JP2009508191A patent/JP5277159B2/ja not_active Expired - Fee Related
- 2007-05-09 TW TW096116359A patent/TW200815366A/zh unknown
- 2007-05-09 AR ARP070102010A patent/AR060992A1/es not_active Application Discontinuation
- 2007-05-10 UY UY30339A patent/UY30339A1/es not_active Application Discontinuation
-
2008
- 2008-11-06 MY MYPI20084448A patent/MY148096A/en unknown
- 2008-11-09 IL IL195177A patent/IL195177A0/en unknown
- 2008-11-10 US US12/267,918 patent/US7713988B2/en not_active Expired - Fee Related
- 2008-12-04 NO NO20085066A patent/NO20085066L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009536627A5 (enExample) | ||
| JP2009536626A5 (enExample) | ||
| JP2009536629A5 (enExample) | ||
| RU2008148838A (ru) | Фениламинобензоксазолзамещенные карбоновые кислоты, способ их получения и их применение в качестве лекарственных средств | |
| Huang et al. | Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro | |
| Ampofo et al. | Regulatory mechanisms of somatostatin expression | |
| JP2005501861A5 (enExample) | ||
| RU2010115748A (ru) | (карбоксилалкиленфенил) фенилоксаламиды, способ их получения и их применение в качестве лекарственного средства | |
| RU2010115747A (ru) | (циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства | |
| RU2009120679A (ru) | Новый дифенилазетидинон, замещенный пиперазин-1-сульфокислотой, обладающий улучшенными фармакологическими свойствами | |
| Shams et al. | The pathophysiology of osteoporosis after spinal cord injury | |
| CN1637149A (zh) | 新型用途 | |
| RU2008105756A (ru) | Производные 1,4-бензотиазепин-1,1-диоксида, способ их получения, лекарственное средство, содержащее эти соединения и их применение в качестве гиполипидемических средств | |
| RU2009122470A (ru) | Новые бензилзамещенные производные 1,4-бензотиепин-1,1-диоксида, способ их получения, лекарственные средства, содержащие такие соединения, и их применение | |
| RU2009108280A (ru) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение | |
| Kim et al. | Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression | |
| RU2007142657A (ru) | Производные азола в качестве ингибиторов липаз и фосфолипаз | |
| JP2007500145A5 (enExample) | ||
| JP2008536884A5 (enExample) | ||
| CN101090895A (zh) | 芳基磺酰胺调节剂 | |
| Kruse et al. | Novel insights into M3 muscarinic acetylcholine receptor physiology and structure | |
| Tong et al. | A review of signaling transduction mechanisms in osteoclastogenesis regulation by autophagy, inflammation, and immunity | |
| JP2007531730A5 (enExample) | ||
| Tang et al. | Water solution of onion crude powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-κB pathways | |
| Cha et al. | Parathyroid hormone accelerates decompensation following left ventricular hypertrophy |